本文轉(zhuǎn)載自肖恩大俠

　　反向并購再上市，Valeritas納斯達(dá)克掛牌

　　大麻也瘋狂！Therapix Biosciences納斯達(dá)克成功IPO

　　FGFR3靶點膀胱癌單抗再獲3000萬美元B輪融資

　　點石成金，原GSK高管受資本青睞，新公司再獲3040萬美金B(yǎng)輪投資

　　大手筆！Hologic 16.5億美元收購Cynosure進(jìn)軍醫(yī)美

　　Xenon制藥股價狂跌44%，痤瘡藥臨床試驗終止

　　IPO掛牌

　　1.一次性胰島素泵生產(chǎn)商Valeritas納斯達(dá)克上市

　　概要：Valeritas于3月23日在納斯達(dá)克IPO發(fā)行股票，通過以每股10美元的價格出售525萬股股份，希望籌集5250萬美元。Valeritas是一家專注糖尿病治療的醫(yī)療技術(shù)公司，致力于創(chuàng)新型藥物供應(yīng)解決方案的開發(fā)和商業(yè)化，為患者帶去臨床和人道解決方案。值得一提的是，Valeritas曾于去年3月撤回上市計劃，之后縮減規(guī)模重新申請上市。

　　相關(guān)報道：

　　Valeritas prices IPO at $10, within the range

　　Mar 23, 2017

　　Valeritas Holdings, which markets a disposable device that delivers insulin therapy for Type 2 diabetes, raised $53 million by offering 5.3 million shares at $10, within the range of $9 to $11. Valeritas Holdings plans to list on the Nasdaq under the symbol VLRX. Cowen & Company and Wedbush PacGrow acted as lead managers on the deal.

　　The article Valeritas prices IPO at $10, within the range originally appeared on IPO investment manager Renaissance Capital's web.

　　PS: Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

　　Source: NASDAQ

　　https://www.nasdaq.com/article/valeritas-prices-ipo-at-10-within-the-range-cm764581

　　2. 以色列大麻制藥公司Therapix Biosciences納斯達(dá)克成功IPO

　　概要：Therapix Biosciences在納斯達(dá)克IPO發(fā)行200萬股ADS，發(fā)行價為6美元每ADS，其原先預(yù)定價位為5-7美元每ADS。Therapix Biosciences是一家以色列大麻制藥公司，現(xiàn)階段公司正在開展兩個大麻藥物臨床試驗，分別是處于臨床2b期適應(yīng)癥為圖雷特氏綜合癥的THX-TS01和臨床1期針對輕度認(rèn)知障礙的THX-ULD01。

　　相關(guān)報道：

　　Therapix Biosciences Ltd. Announces Pricing of U.S. InitialPublic Offering and NASDAQ Listing

　　Mar 22, 2017

　　Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE:THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced the pricing of its initial publicoffering in the United States of 2,000,000 American Depository Shares("ADSs"). Each ADS, representing 40 ordinary shares of the Company,is offered at a price to the public of $6.00.

　　The gross proceeds to Therapix from this offering are expected tobe $12,000,000, prior to deducting underwriting discounts, commissions and other offering expenses. Therapix has granted the underwriters a 45-day optionto purchase up to an additional 300,000 ADSs to cover over-allotments, if any.

　　Therapix plans to use the net proceeds from the offering to advance the formulation and clinical development efforts for its two lead product candidates, including Phase II clinical trials, and for working capital and other general corporate purposes.

　　Therapix's ADSs are scheduled to begin trading on the NASDAQ Capital Market on March 22, 2017, under the symbol "TRPX". The offering is expected to close on or about March 27, 2017, subject to customary closing conditions.

　　Source: PR News Wire

　　https://www.prnewswire.com/news-releases/therapix-biosciences-ltd-announces-pricing-of-us-initial-public-offering-and-nasdaq-listing-616794734.html

　　私募融資

　　1.藥物公司BioClin宣布完成3000萬美元的B輪融資

　　概要：BioClin Therapeutics宣布完成了3000萬美元的B輪融資。此輪投資是由Sofinnova Ventures和Ysios Capital領(lǐng)投的，原投資方HealthCap、Life Sciences Partners(LSP)以及TeklaCapital Management繼續(xù)跟投。BioClin Therapeutics是一家臨床階段藥物公司，該公司候選藥物B-701是一種靶向FGFR3（成纖維細(xì)胞生長因子受體3）的人源單克隆抗體，有成為領(lǐng)域內(nèi)首個藥物（first-in-class）的潛力。該輪融資能夠使BioClin擴大使用B-701與多西紫杉醇聯(lián)合的1b/2期試驗，并啟動了一項評估B-701聯(lián)用atezolizumab單抗的1b/2期試驗。

　　相關(guān)報道：

　　BioClin Gets $30M to Back More Bladder Cancer Drug Trials

　　Mar 22, 2017

　　BioClin Therapeutics has raised $30 million in funding to move forward with more tests of its experimental treatment for bladder cancer.

　　New investors Sofinnova Ventures and Ysios Capital led the Series B round of financing for San Ramon, CA-based BioClin. Earlier investors HealthCap, Life Sciences Partners, and Tekla Capital Management also participated in the investment. BioClin says it has now raised a total of $59million from investors.

　　BioClin’s lead drug candidate, B-701, is a monoclonal antibody developed to target fibroblast growth factor receptor 3 (FGFR3), a protein thatis often mutated in patients with bladder cancer. So far, BioClin has testedits treatment in two Phase 1 clinical trials, one of which studied patients with advanced solid tumors, including bladder cancer.

　　With the new capital, BioClin says it will test its drug inpatients who have metastatic bladder cancer or metastatic urothelial carcinoma and have either relapsed or failed to respond to first-line cancer treatments.The company says it will also expand a Phase 1b/2 clinical trial evaluating its drug in combination with the chemotherapy docetaxel.

　　BioClin also plans to start a a Phase 1b/2 trial evaluating itsdrug in combination with atezolizumab (Tecentriq), a Genentech immunotherapy drug that the FDA approved last year to treat the most common form of bladder cancer.

　　Source: Xconomy

　　https://www.xconomy.com/san-francisco/2017/03/22/bioclin-lands-30m-to-back-more-bladder-cancer-drug-trials/

　　2. 英國新藥研發(fā)公司Pulmocide 完成3040萬美元B輪融資

　　概要：Pulmocide是一家成立于2013年的英國公司,近日宣布完成了總額為3040萬美元的B輪融資，業(yè)內(nèi)知名風(fēng)險投資機構(gòu)SROne領(lǐng)投。目前公司有兩款擁有自主知識產(chǎn)權(quán)的產(chǎn)品，一款叫做PC786的產(chǎn)品能以霧狀制劑的形式，被患者吸入呼吸道，治療呼吸道合胞病毒感染；另一款產(chǎn)品PC945能針對肺部的真菌感染。B輪融資將用于這兩款創(chuàng)新化合物到早期臨床階段。Pulmocide公司首席執(zhí)行官Rapeport博士曾出任葛蘭素史克的高級副總裁長達(dá)6年，并曾擔(dān)任“卓越中心”（Centre of Excellence）的呼吸疾病主任。先前，Rapeport博士曾出任一家初創(chuàng)公司Respivert的首席執(zhí)行官，并幫助它在2010年被強生以近1億美元的價格收購。

　　相關(guān)報道：

　　Ex-GSK team raises $30M for respiratory infection trials

　　Mar 20, 2017

　　Researchers who worked at GlaxoSmithKline before leading RespiVertto a takeover by Johnson & Johnson have raised $30.4 million (?24.5million) for their latest venture, Pulmocide. The Series B will allow Pulmocideto take inhaled treatments for respiratory syncytial virus (RSV) and pulmonary aspergillosis through early clinical trials.

　　New investor SR One, the VC arm of GSK, led the round with the support of backers who helped Pulmocide to its ?17 million Series A in 2013,including SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovationand Touchstone Innovations. London, United Kingdom-based Pulmocide has attracted the big name financiers on the strength of its management team andthe potential of the two candidates they have started to develop.

　　“Pulmocide's core asset is the management team's proprietary expertise in the design of highly potent compounds with extended lung retentiontime and limited systemic exposure. This has enabled the development of two anti-infective drugs for serious diseases of the lung, where an inhaled therapy should deliver the optimal clinical outcome,” SR One Partner Matthew Foy saidin a statement.

　　Many on the management team, including CEO Garth Rapeport, M.D.and CSO Pete Strong, Ph.D., list stints at GSK on their résumés. Rapeport,Strong and other members of the Pulmocide team subsequently showed they couldturn the expertise in inhaled medicines they accrued at GSK and elsewhere intobiotech success when they set up RespiVert. J&J bought the biotech and itspipeline of programs in COPD, cystic fibrosis and severe asthma in 2010 for an undisclosed sum reported by The Telegraph to be around $100 million.

　　Source: Fierce Biotech

　　https://www.fiercebiotech.com/biotech/ex-gsk-team-raises-30m-for-respiratory-infection-trials

　　并購

　　1. Hologic 16.5億美元收購Cynosure進(jìn)軍醫(yī)美界

　　概要：Hologic（NASDAQ：HOLX）最終確定收購Cynosure（NASDAQ：CYNO）,收購價為16.5億美元,每股66美元，Hologic是一家診斷產(chǎn)品、醫(yī)療成像系統(tǒng)和手術(shù)產(chǎn)品制造商，Cynosure是一家專注于產(chǎn)品用于非侵入性身體造型，脫毛，皮膚再生的女性健康的公司，并購后Hologic戰(zhàn)略定位為打造女性健康第一醫(yī)療品牌。

　　相關(guān)報道：

　　Hologic (HOLX) Completes Acquisition of Cynosure (CYNO)

　　Mar 22, 2017

　　Hologic,Inc. (Nasdaq: HOLX) announced today that it has completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies, for$66 per share in cash.

　　"Weare pleased to complete our acquisition of Cynosure, and look forward toworking with Michael Davin and the entire Cynosure team to achieve even greater success in the large, rapidly growing medical aesthetics market," saidSteve MacMillan, Hologic's Chairman, President and Chief Executive Officer."Acquiring Cynosure, combined with divesting our blood screening business,fundamentally reshapes our business portfolio and makes us a stronger, faster-growing company."

　　Thetender offer by a subsidiary of Hologic for all the outstanding shares ofCynosure Class A Common Stock expired as scheduled at midnight ET on March 21,2017. A total of 17,047,830 shares of Cynosure Class A Common Stock,representing approximately 70.6% of Cynosure's outstanding shares, were validly tendered into and not validly withdrawn from the tender offer. As a result,Hologic and its subsidiary have accepted for payment and will promptly pay forall shares that were validly tendered and not validly withdrawn.

　　Source: Street Insider

　　https://www.streetinsider.com/Corporate+News/Hologic+(HOLX)+Completes+Acquisition+of+Cynosure+(CYNO)/12695012.html

　　行業(yè)盤點

　　1.Xenon制藥候選藥物2期臨床未取得積極結(jié)果

　　概要：Xenon制藥(NASDAQ：XENE)宣布，該公司治療中重度痤瘡的重要候選藥物XEN801在2期臨床試驗中未能達(dá)到關(guān)鍵藥效學(xué)終點。具體來說，與安慰劑相比，臨床數(shù)據(jù)無法證明從基線到第12周的病變計數(shù)在統(tǒng)計學(xué)上有明顯差異，該公司將終止發(fā)展此候選藥物，Xenon制藥股價應(yīng)聲下跌44%。

　　相關(guān)報道：

　　Xenon acne drug misses efficacy endpoints in phase 2

　　Mar 24, 2017

　　A phase 2trial of Xenon Pharmaceuticals’ acne candidate XEN801 has missed its primary and key secondary efficacy endpoints. The comprehensive failure prompted Xenonto admit the data don’t support continued development of XEN801 and wiped 44%off its stock price in premarket trading.

　　Xenonenrolled 165 patients with moderate-to-severe facial acne and randomized them toreceive either a gel formulation of XEN801 or placebo. After 12 weeks in which participants applied a gel to their faces each evening, investigators looked for changes against baseline. The study’s primary endpoint was the percent change in lesion count after 12 weeks. Secondary endpoints looked at lesioncounts after four and eight weeks, and the change on an investigator assessmentscale.

　　Managementat Xenon thought small molecule SCD1 inhibitor XEN801 could improve outcomes byreducing the size and number of sebaceous glands, but the data fell well shortof expectations. XEN801 failed to outperform placebo against the primaryefficacy endpoint. And it came up short against “key secondary efficacyendpoints.”

　　Faced with a clean sweep of negative efficacy endpoints, Xenon CEO Simon Pimstone,M.D., Ph.D. held his hands up and admitted it looks like the end of the linefor XEN801.

　　PS:這種因臨床試驗或其他重大影響而暴漲暴跌的情形非常多，如能提前研判或及時知曉/預(yù)測，這能力該多強啊。

　　Source: Fierce Biotech

　　https://www.fiercebiotech.com/biotech/xenon-acne-drug-misses-efficacy-endpoints-phase-2

　　以上，難免有疏漏或不正確之處，請多多指出，并在文下留言處留言，謝謝！